Eli Lilly reports Q3 2026 earnings before the open on October 29 amid consensus estimates for revenue near $22.6 billion (up roughly 28% year-over-year) and EPS around $6.36–$6.61. Trader consensus priced at a 60.5% probability of no beat reflects elevated expectations after four consecutive large surprises, recent downward revisions to full-year 2026 EPS forecasts, and potential one-time R&D charges tied to acquisitions that could pressure the bottom line despite strong Mounjaro and Zepbound demand. With shares trading near $1,288 and options implying a ±6% move, the market-implied odds emphasize the challenge of clearing a high bar set by prior outperformance and analyst optimism.